MBIO - MUSTANG BIO, INC.

0.754
-0.009   -1.247%

Share volume: 87,590
Last Updated: 04-24-2026
Pharmaceutical Products/Pharmaceutical Preparations: -0.11%

PREVIOUS CLOSE
CHG
CHG%
$0.76
-0.01
-0.01%
5D - 1M - 3M - 1Y - 3Y - 5Y - 10Y - 15Y
Overview Charts Financials Fundamental analysis Historical prices Events Documents Notes Dividends
Fundamental analysis
15%
Profitability 8%
Dept financing 6%
Liquidity 50%
Performance 15%
Company vs Stock growth
vs
+ Add row to compare
Performance
5 Days
-1.44%
1 Month
4.29%
3 Months
-26.08%
6 Months
-49.73%
1 Year
-35.00%
2 Year
218.14%
Key data
Stock price
$0.75
P/E Ratio 
N/A
DAY RANGE
$0.75 - $0.80
EPS 
-$0.42
52 WEEK RANGE
$0.53 - $7.00
52 WEEK CHANGE
-$35.00
MARKET CAP 
0.000
YIELD 
N/A
SHARES OUTSTANDING 
7.577 M
DIVIDEND
$0.00
EX-DIVIDEND DATE
01-16-2025
NEXT EARNINGS DATE
04-29-2025
BETA 
37.22
PUBLIC FLOAT 
$0
AVERAGE 10 VOLUME 
$53,343
AVERAGE 30 VOLUME 
$39,066
Company detail
CEO: Manuel Litchman
Region: US
Website: mustangbio.com
Employees: 100
IPO year: 2017
Issue type: Common Stock
Market: XNAS
Industry: Pharmaceutical Products/Pharmaceutical Preparations
Sector: Manufacturing

Mustang Bio, Inc., a clinical-stage biopharmaceutical company, focuses on translating medical breakthroughs in cell and gene therapies into potential cures for hematologic cancers, solid tumors, and rare genetic diseases. The company develops MB-107 and MB-207, a gene therapy program for X-linked severe combined immunodeficiency, a rare genetic immune system condition.

Recent news